As columnist Mary Shaniqua looks to the future, she remembers when she was far more active — and wonders if that could be a ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

Columnist Mary Shaniqua, who undergoes monthly transfusions because of sickle cell, thanks the blood donors who make it ...

After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

The researchers found that people who were economically deprived, even in the absence of sickle cell disease, had more ...

Richard Bayliss is 44 years old and has sickle cell disease with hemoglobin SS disease. He’s in the final year of a master’s ...

Columnist Oluwatosin Adesoye had faced many sickle cell complications, but her hypothyroidism diagnosis was, at first, overwhelming.

The Bill and Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support the development of a new gene-editing medicine for sickle cell disease (SCD), the company said. ...